Regulus Therapeutics Inc.
RGLSDelisted Jun 25, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001505512
Regulus Therapeutics Inc. was delisted on Jun 25, 2025; its insiders filed their last Form 4 on Jun 27, 2025; 75 institutions reported holding it in 13F filings for Q1 2025, worth $107.0M in total; no superinvestor held it.
Q3 2023 vs. Q2 2023
How the institutions holding Regulus Therapeutics Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 26 | 1 | 25 | 0 |
| Shares | 10.2M | 675 | 10.9M | +727.3K (+7.1%) |
| Value | $15.0M | $0 | $15.0M | +$51.7K (+0.3%) |
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (2)
Institutions that held Regulus Therapeutics Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 25,921 | $36.0K | 0.00% |
| JPMorgan Chase & Co | 20 | $28 | 0.00% |
Sold out (2)
Institutions that held Regulus Therapeutics Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| LPL Financial LLC | 18,502 | $27.2K |
| Barclays PLC | 225 | $331 |
Not filed for Q3 2023 yet (1)
Institutions that held Regulus Therapeutics Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Endurance Wealth Management, Inc. | 675 | $0 |